Leitlinie „Behandlung der Akne“ - AWMF

013/017 - Behandlung der Akne aktueller Stand: 02/2010
korrigierte Fassung: 10/2011
290. Lachnit-Fixson U, Kaufmann J. [Therapy of androgenization symptoms: double blind
study of an antiandrogen preparation (SH B 209 AB) against neogynon (author's
transl)]. Med Klin. 1977; 72: 1922-6.
291. Erkkola R, Hirvonen E, Luikku J, Lumme R, Mannikko H, Aydinlik S. Ovulation
inhibitors containing cyproterone acetate or desogestrel in the treatment of
hyperandrogenic symptoms. Acta Obstet Gynecol Scand. 1990; 69: 61-5.
292. Charoenvisal C, Thaipisuttikul Y, Pinjaroen S, Krisanapan O, Benjawang W, Koster
A, Doesburg W. Effects on acne of two oral contraceptives containing desogestrel and
cyproterone acetate. Int J Fertil Menopausal Stud. 1996; 41: 423-9.
293. Dieben TO, Vromans L, Theeuwes A, Bennink HJ. The effects of CTR-24, a biphasic
oral contraceptive combination, compared to Diane-35 in women with acne.
Contraception. 1994; 50: 373-82.
294. Aydinlik S, Lachnit-Fixson U, Lehnert J. [Reduced estrogen ovulation inhibitor in
acne therapy. Double-blind study comparing Diane-35 to Diane]. Fortschr Med. 1986;
104: 547-50.
295. Colver GB, Mortimer PS, Dawber RP. Cyproterone acetate and two doses of
oestrogen in female acne; a double-blind comparison. Br J Dermatol. 1988; 118: 95-9.
296. Fugere P, Percival-Smith R, Lussier-Cacan S, Tetrault C, Farquhar DJ. The
comperative efficacy and safety of Diane-35 versus Diane-50 in the treatment of
moderate to severe acne and seborrhea: 12-month results. Recent Res Gynecol
Endocrinol. 1988; 1: 590-608.
297. Monk BE, Almeyda JA, Caldwell IW, Green B, Pelta D, Leonard J, Du Vivier A,
Johnson K, Tolowinska I. Efficacy of low-dose cyproterone acetate compared with
minocycline in the treatment of acne vulgaris. Clin Exp Dermatol. 1987; 12: 319-22.
298. Seaman HE, de Vries CS, Farmer RD. Differences in the use of combined oral
contraceptives amongst women with and without acne. Hum Reprod. 2003; 18: 515-
21.
299. Tan J. Hormonal treatment of acne: Review of current best evidence. J Cut Med
Surgery. 2005; 8: 11-15.
300. Kaiser E. [Effect of a new hormonal contraceptive (Neo-Eunomin) in females with
androgenization symptoms]. Geburtshilfe Frauenheilkd. 1984; 44: 651-5.
301. Worret I, Arp W, Zahradnik HP, Andreas JO, Binder N. Acne resolution rates: results
of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA
(Belara) and EE/LNG (Microgynon). Dermatology. 2001; 203: 38-44.
302. Moore C, Luderschmidt C, Moltz L, Oettel M, Klinger G, Schreiber G.
Antiandrogenic propertiesof the dienogest-containing oral contrceptive Valette. Drugs
of Today (Barc). 1999; 35: 69-78.
303. Palombo-Kinne E, Schellschmidt I, Schumacher U, Graser T. Efficacy of a combined
oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the
treatment of papulopustular acne in comparison with placebo and 0.035 mg
ethinylestradiol/2 mg cyproterone acetate. Contraception. 2009; 79: 282-9.
304. Foster RH, Wilde MI. Dienogest. Drugs. 1998; 56: 825-33; discussion 34-5.
305. Maloney JM, Dietze P, Jr., Watson D, Niknian M, Lee-Rugh S, Sampson-Landers C,
Korner P. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl
Seite 124 von 136